GSS.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Diagnostics & Research

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$22M	+46.9%	$-0.05	$-0.05–$-0.05	—	1
2028	$26M	+19.3%	$-0.03	$-0.03–$-0.03	—	1
2029	$142M	+444.6%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 6 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-08-25	$0.03	$-0.02	-165.0%
2025-02-25	$0.00	$-0.07	-1509.8%
2024-10-30	$-0.04	$-0.04	+14.2%
2024-02-21	$-0.03	$-0.07	-113.2%
2023-08-31	$-0.05	$-0.05	+5.4%
2023-02-22	$-0.02	$-0.04	-115.3%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GSS.AXGenetic Signatures Limited	$0.07	-9.88%	$17M	—
ATX.AXAmplia Therapeutics Limited	$0.12	+0.00%	$62M	—
BMT.AXBeamtree Holdings Limited	$0.10	+0.00%	$31M	—
CMP.AXCompumedics Limited	$0.28	+0.00%	$55M	—
CTE.AXCryosite Limited	$1.18

Genetic Signatures Limited

Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.

www.geneticsignatures.com

Employees: 117
IPO / List date: Mar 30, 2015
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds GSS.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in GSS.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GSS.AX yet.